Cancer Conference Update
Potential Role of PROTAC ER Degraders in Therapy for HR-Positive Metastatic Breast Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:45:46
- Mas informaciones
Informações:
Sinopsis
Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville discusses emerging evidence with proteolysis-targeting chimera estrogen receptor degraders for HR-positive metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.
